文献速递儿童感染儿童心血管与肾脏

住院儿童万古霉素联用哌拉西林/他唑巴坦与急性肾损伤的相关性

Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children.
PubMed 文献 · JAMA Pediatr · 2017-12-04

这项回顾性队列研究纳入1915例住院儿童,比较静脉万古霉素联合哌拉西林/他唑巴坦与其他抗假单胞菌β-内酰胺类抗生素联合治疗时急性肾损伤(AKI)的风险。结果显示,联合哌拉西林/他唑巴坦组AKI发生率为11.7%,调整混杂因素后,每日AKI风险显著增高(调整OR 3.40,95%CI 2.26-5.14)。

要点

  • 住院儿童联用万古霉素与哌拉西林/他唑巴坦的AKI发生率为11.7%。
  • 调整后,该联合方案每日AKI风险是其他β-内酰胺类的3.40倍。
  • 经验性选择抗生素时需警惕该联合方案的潜在肾毒性风险。

核心结论

  • 静脉万古霉素联合哌拉西林/他唑巴坦可能增加住院儿童急性肾损伤的风险。

研究设计与样本

  • 回顾性队列研究,纳入2007年1月1日至2012年12月31日期间6家美国大型儿童医院中住院≥3天且接受静脉万古霉素联合一种抗假单胞菌β-内酰胺类抗生素治疗的6月龄至18岁儿童,排除有基础肾病或入院第0-2天血清肌酐异常者,共纳入1915例。

主要发现

  • 1915例患儿中,866例(45.2%)为女性,1049例(54.8%)为男性,1049例(54.8%)种族/民族为白人,中位年龄(四分位距)为5.6(2.1-12.7)岁。
  • 接受联合治疗的患儿中,157例(8.2%)发生抗生素相关性急性肾损伤;其中接受万古霉素联合哌拉西林/他唑巴坦治疗的1009例中有117例(11.7%)发生急性肾损伤。
  • 调整年龄、重症监护级别、肾毒性药物暴露和医院后,万古霉素联合哌拉西林/他唑巴坦相比万古霉素联合其他抗假单胞菌β-内酰胺类抗生素,每个住院日发生急性肾损伤的调整比值比为3.40(95%CI 2.26-5.14)。

关键数值与推荐

  • 急性肾损伤采用KDIGO标准定义,基于住院第0-2天至第3-7天血清肌酐水平的变化。
  • 主要结局为住院第3-7天且在接受联合治疗2天内发生的急性肾损伤。

临床怎么用

  • 儿科医生在经验性选择抗生素时,应认识到万古霉素联合哌拉西林/他唑巴坦可能增加住院儿童急性肾损伤的额外风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: β-Lactam antibiotics are often coadministered with intravenous (IV) vancomycin hydrochloride for children with suspected serious infections. For adults, the combination of IV vancomycin plus piperacillin sodium/tazobactam sodium is associated with a higher risk of acute kidney injury (AKI) compared with vancomycin plus 1 other β-lactam antibiotic. However, few studies have evaluated the safety of this combination for children. OBJECTIVE: To assess the risk of AKI in children during concomitant therapy with vancomycin and 1 antipseudomonal β-lactam antibiotic throughout the first week of hospitalization. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study focused on children hospitalized for 3 or more days who received IV vancomycin plus 1 other antipseudomonal β-lactam combination therapy at 1 of 6 large children's hospitals from January 1, 2007, through December 31, 2012. The study used the Pediatric Health Information System Plus database, which contains administrative and laboratory data from 6 pediatric hospitals in the United States. Patients with underlying kidney disease or abnormal serum creatinine levels on hospital days 0 to 2 were among those excluded. Patients 6 months to 18 years of age who were admitted through the emergency department of the hospital were included. Data were collected from July 2015 to March 2016. Data analysis took place from April 2016 through July 2017. (Exact dates are not available because the data collection and analysis processes were iterative.). MAIN OUTCOMES AND MEASURES: The primary outcome was AKI on hospital days 3 to 7 and within 2 days of receiving combination therapy. Acute kidney injury was defined using KDIGO criteria and was based on changes in serum creatinine level from hospital days 0 to 2 through hospital days 3 to 7. Multiple logistic regression was performed using a discrete-time failure model to test the association between AKI and receipt of IV vancomycin plus piperacillin/tazobactam or vancomycin plus 1 other antipseudomonal β-lactam antibiotic. RESULTS: A total of 1915 hospitalized children who received combination therapy were identified. Of the 1915 patients, a total of 866 (45.2%) were female and 1049 (54.8%) were male, 1049 (54.8%) were identified as white in race/ethnicity, and the median (interquartile range) age was 5.6 (2.1-12.7) years. Among the cohort who received IV vancomycin plus 1 other antipseudomonal β-lactam antibiotic, 157 patients (8.2%) had antibiotic-associated AKI. This number included 117 of 1009 patients (11.7%) who received IV vancomycin plus piperacillin/tazobactam combination therapy. After adjustment for age, intensive care unit level of care, receipt of nephrotoxins, and hospital, IV vancomycin plus piperacillin/tazobactam combination therapy was associated with higher odds of AKI each hospital day compared with vancomycin plus 1 other antipseudomonal β-lactam antibiotic combination (adjusted odds ratio, 3.40; 95% CI, 2.26-5.14). CONCLUSIONS AND RELEVANCE: Coadministration of IV vancomycin and piperacillin/tazobactam may increase the risk of AKI in hospitalized children. Pediatricians must be cognizant of the potential added risk of this combination therapy when making empirical antibiotic choices.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Downes KJ, Cowden C, Laskin BL, et al. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children. JAMA Pediatr. 2017. PMID: 28973124. doi:10.1001/jamapediatrics.2017.3219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。